In a report released today, Robert LeBoyer from Noble Financial maintained a Buy rating on PDS Biotechnology (PDSB – Research Report), with a price target of $17.00. The company’s shares opened today at $5.35.
LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Tonix Pharma, and GeoVax Labs. According to TipRanks, LeBoyer has an average return of -9.3% and a 24.87% success rate on recommended stocks.
PDS Biotechnology has an analyst consensus of Strong Buy, with a price target consensus of $18.75, representing a 250.47% upside. In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $23.00 price target.
See the top stocks recommended by analysts >>
Based on PDS Biotechnology’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $9.66 million. In comparison, last year the company had a GAAP net loss of $8.47 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
Read More on PDSB:
- PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update
- PDS Biotechnology reports Q2 EPS (37c), consensus (35c)
- PDS announces submission of Phase 3 protocol to FDA to initiate VERSATILE-003
- PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
- PDSB Earnings this Week: How Will it Perform?
